[1] GORE J M, SPENCER F A, GURFINKEL E P, et al. Thrombocytopenia in patients with an acute coronary syndrome (from the global registry of acute coronary events[GRACE])[J]. Am J Cardiol,2009,103(2):175-180
[2] YADAV M, GÉNÉREUX P, GIUSTINO G, et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention[J]. Can J Cardiol,2016,32(2):226-233
[3] LIPPI G, PLEBANI M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact[J]. Clin Chem Lab Med,2012,50(8):1281-1285
[4] O'MALLEY T, LANGHORNE P, ELTON R A, et al. Platelet size in stroke patients[J]. Stroke,1995,26(6):995-999
[5] VANWIJK M J, VANBAVEL E, STURK A, et al. Microparticles in cardiovascular diseases[J]. Cardiovasc Res,2003,59(2):277-287
[6] 高亚玥, 赵永强, 王书杰. 肝素诱导的血小板减少症发病率及其抗体阳性率调查[J]. 中华内科杂志, 2013, 52(9):734-736
[7] WARKENTIN T E, SHEPPARD J A, HORSEWOOD P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia[J]. Blood,2000,96(5):1703-1708
[8] 赵永强. 肝素诱导的血小板减少症诊断与治疗常见问题[J]. 中国实用内科杂志, 2013, 33(5):366-368
[9] CUKER A, AREPALLY G M, CHONG B H, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia[J]. Blood Adv,2019,2(22):3360-3392
[10] 中国医师协会心血管内科医师分会血栓防治专业委员会, 《中华医学杂志》编辑委员会. 肝素诱导的血小板减少症中国专家共识(2017)[J]. 中华医学杂志, 2018, 98(6):408-417
[11] SELLENG K, SELLENG S, RASCHKE R, et al. Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin[J]. Am J Hematol,2005,78(3):188-192
[12] TAKAHASHI H, MUTO S, NAKAZAWA E, et al. Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient[J]. Clin Nephrol,2003,59(6):458-462
[13] MEGALOPOULOS A, VASILIADIS K, TSACHALIS T, et al. Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome[J]. Int Angiol,2006,25(1):84-89
[14] ZAID G, DAWOD S, ROSENSCHEIN U. Immune thrombocytopenic purpura and myocardial infarction: a dilemma of management[J]. Isr Med Assoc J,2013,15(12):775-776
[15] PETERS M N, PRESS C D, MOSCONA J C, et al. Acute profound thrombocytopenia secondary to local abciximab infusion[J]. Proc (Bayl Univ Med Cent),2012,25(4):346-348
[16] SAID S M, HAHN J, SCHLEYER E, et al. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment[J]. Clin Res Cardiol,2007,96(2):61-69
[17] VELIBEY Y, GOLCUK Y, EKMEKCI A, et al. Tirofiban-induced acute profound thrombocytopenia: what is the optimal approach to treatment? Platelets,2015,26(2):197-198
[18] HUXTABLE L M, TAFRESHI M J, RAKKAR A N. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists[J]. Am J Cardiol,2006,97(3):426-429
[19] Azarm T, Sohrabi A, Mohajer H, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel: a case report and review of the literature[J]. J Res Med Sci,2011,16(3):353-357
[20] BENNETT C L, KIM B, ZAKARIJA A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project[J]. J Am Coll Cardiol,2007,50(12):1138-1143
[21] JACOB S, DUNN B L, QURESHI Z P, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR)[J]. Semin Thromb Hemost,2012,38(8):845-853
[22] MACHIN N, RAGNI M V, COMER D M, et al. Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study[J]. Thromb Res,2018,172:80-85
[23] SINKOVIČ A, MAJAL M. The impact of thrombocytopenia on outcome in patients with acute coronary syndromes: A single center retrospective study[J]. Biomed Res Int,2015,2015:907304
[24] L S, P, Y C. Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review[J]. BMC Cardiovasc Disord,2015,15:101